Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

OSAKA, Japan--(BUSINESS WIRE)--Mar 19, 2026-

Shionogi enrols first patients in Esprit trial for Pompe disease

Shionogi has enrolled the first patients in its global Phase II clinical trial, Esprit, assessing the investigational drug S-606001 in adults with LOPD.The post Shionogi enrols first patients in Esprit trial for Pompe disease appeared first on Hospital Management.